Showing 21-30 of 2403 results for "".
- Thumbs Down for Neothetics, Inc.'s LIPO-202; Stock Plummetshttps://practicaldermatology.com/news/thumbs-down-for-neothetics-incs-lipo-202/2458145/Neothetics, Inc.’s LIPO-202 for the reduction of submental subcutaneous fat failed to demonstrate improvement on any efficacy measurements or separation from placebo in a Phase 2 proof-of-concept trial. Neothetics Inc. shares droppe
- Soligenix, Inc.’s SGX302 (Synthetic Hypericin) Demonstrates “Clear Biological Signal” in Phase 2a PsO Studyhttps://practicaldermatology.com/news/sgx302-synthetic-hypericin-demonstrates-clear-biological-signal-in-phase-2a-pso-study/2461854/Soligenix, Inc.’s SGX302 (synthetic hypericin) showed a clear
- Chicago Dermatologist Dr. Amy S. Paller Wins American Skin Association’s David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/chicago-dermatologist-dr-amy-s-paller-wins-american-skin-associations-david-martin-carter-mentor-award/2460802/Amy S. Paller, MD of the Feinberg School of Medicine at Northwestern University in Chicago received the American Skin Association's David Martin Carter Mentor Award. For more than three decades, ASA's David Martin Carter Mentor Award has honored members of th
- Is Separating the Good Skin T Cells from the Bad Ones a Key to Treating Psoriasis and Vitiligo?https://practicaldermatology.com/news/is-separating-the-good-skin-t-cells-from-the-bad-ones-a-key-to-treating-psoriasis-and-vitiligo/2462162/New research highlights ways to remove immune cells that cause autoimmune skin diseases such as psoriasis and vitiligo without affecting protective cells that fight infection and cancer. Tissue-resident T cells or TRM cells fight infections and cancerous cells in the skin, but
- Robert T. Kelley of Caliber Imaging & Diagnostics Named Vice President of US Saleshttps://practicaldermatology.com/news/20140305-robert_t_kelley_of_caliber_imaging__diagnostics_named_vice_president_of_us_sales/2459325/Caliber Imaging and Diagnostics has declared Robert T. Kelley vice president of US sales. Kelley, originally director of clinical sales since 2011, was due for a promotion. "We are delighted to promote Bob to Vice President of Sales, just as we were truly fortunate when he agreed to join
- FDA Clears DeepX Diagnostics Inc.'s DermoSight for Telederm Screening of Suspicious Lesionshttps://practicaldermatology.com/news/fda-clears-deepx-diagnostics-incs-dermosight-for-telederm-screening-of-suspicious-lesions/2461763/The US Food and Drug Administration (FDA) has cleared DeepX Diagnostics Inc.’s digital dermatoscope DermoSight for teledermatology screening of suspected skin cancer lesions. DermoSight is currently cle
- One to Watch: AnaptysBio Inc.’s Imsidolimab (IL-36R) Shows Promise in GPPhttps://practicaldermatology.com/news/one-to-watch-imsidolimab-il-36r-shows-promise-in-gpp/2462052/AnaptysBio, Inc.’s Imsidolimab (IL-36R) performed well in in Generalized Pustular Psoriasis (GPP), according to topline results from the Phase 3 GEMINI-1 trial. Imsidolimab is an IgG4 antibody that inhibits the function of the interleukin-36 receptor (IL-36R),
- LEO Pharma A/S Appoints Brian Hilberdink New President of LEO Pharma Inc. United Stateshttps://practicaldermatology.com/news/leo-pharma-as-appoints-brian-hilberdink-new-president-of-leo-pharma-inc-united-states/2461084/LEO Pharma A/S appointed Brian Hilberdink as the new Executive Vice President and President of LEO Pharma Inc. in the United States, effective March 14, 2022. Brian Hilberdink joins LEO Pharma from Novo Nordisk, Inc., in the U.S. where he served as Senior Vice President of Sales.<
- Kubota Vision, LEO Pharma A/S to Screen Novel VAP-1 Inhibitors for Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases/2460351/Kubota Vision Inc. signed an Open Innovation Agreement with LEO Pharma A/S to screen novel Vascular Adhesion Protein-1 (VAP-1) inhibitor compounds for potential therapeutic use in inflammatory skin diseases, such as psoriasis and atopic dermatitis. During R&D activities to develop n
- Dr. Sandra Marchese Johnson, Yoseph Dalia Win Practical Dermatology®'s Best Paper of 2018 Awardhttps://practicaldermatology.com/news/dr-sandra-marchese-johnson-yoseph-dalia-win-practical-dermatologys-best-paper-of-2018-award/2459950/Fort Smith, Arkansas-based dermatologist Sandra Marchese Johnson MD, FAAD and Yoseph Dalia, BS took home Practical Dermatology®’s Best Paper of 2018 award for a Resident Resource Center submission that detailed the first reported case of facial rash following dupilumab